The Effect of Bevacizumab on Corneal Neovascularization
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 主要终点
- The Effect of Bevacizumab on Corneal Neovascularization
研究概览
简要总结
Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.
详细描述
To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization.
Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Corneal Neovascularization
- •Stable lesion
排除标准
- •Autoimmune diseases
研究组 & 干预措施
1
A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up
干预措施: Bevacizumab (Drug)
结局指标
主要结局
The Effect of Bevacizumab on Corneal Neovascularization
时间窗: Compare the results
Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography
次要结局
未报告次要终点
研究者
Joao Nassaralla
Clinical Professor
Instituto de Olhos de Goiania